Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Cash & Equivalents (2019 - 2026)

Immunocore Holdings' Cash & Equivalents history spans 7 years, with the latest figure at $467.7 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 2.63% to $467.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $467.7 million, a 2.63% increase, with the full-year FY2025 number at $467.7 million, up 2.63% from a year prior.
  • Cash & Equivalents hit $467.7 million in Q4 2025 for Immunocore Holdings, down from $498.4 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for IMCR hit a ceiling of $832.8 million in Q1 2024 and a floor of $299.6 million in Q2 2022.
  • Historically, Cash & Equivalents has averaged $445.2 million across 5 years, with a median of $437.3 million in 2021.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 392.75% in 2021 and later plummeted 42.74% in 2025.
  • Tracing IMCR's Cash & Equivalents over 5 years: stood at $320.7 million in 2021, then increased by 21.63% to $390.0 million in 2022, then rose by 13.48% to $442.6 million in 2023, then rose by 2.96% to $455.7 million in 2024, then grew by 2.63% to $467.7 million in 2025.
  • Business Quant data shows Cash & Equivalents for IMCR at $467.7 million in Q4 2025, $498.4 million in Q3 2025, and $487.9 million in Q2 2025.